BSD up on FDA clearance of cervical cancer treatment; Great Basin seeks regulatory sign-off for C. diff test;

> In what CEO Harold Wolcott called a "significant milestone," BSD Medical has received the FDA's OK to sell a heat-therapy system used in the treatment of cervical cancer patients. The company's shares shot up 19% in premarket trading. BSD release | Story

> Great Basin Corporation has submitted a 510(k) application for its first molecular diagnostic test for Clostridium difficile. Great Basin release

> Wake Forest Baptist Medical Center researchers are teaming up with the Department of Veterans Affairs on a research project aimed at advancing the treatment of military personnel suffering from post-traumatic stress disorder and traumatic brain injury. Using a high-tech tool for brain activity imaging called magnetoencephalography, researchers will conduct neurological tests on military veterans with and without a PTSD diagnosis, and with varying levels of impairment. Wake Forest release

> Pittsburgh's Wright Therapy Products, which makes compression devices, has raised about $1.1 million of what the company hopes is a $2 million haul. News

> Retina Implant AG's scientific advisory board is backing the start of the multi-center phase of the company's second human clinical trial. The trial will be expanded across Europe in 5 new sites, including two additional locations in Germany, Oxford, London and Budapest. Retina Implant release

And Finally... In a paper published in the journal Nature Materials, University of Georgia scientists describe a new material that emits a long-lasting, near-infrared glow after a single minute of exposure to sunlight. Lead author Zhengwei Pan said the material has the potential to, among other things, revolutionize medical diagnostics. UGA release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.